Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91054 Erlangen, Germany.
Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91054 Erlangen, Germany.
Int J Mol Sci. 2022 Sep 29;23(19):11524. doi: 10.3390/ijms231911524.
Hepatic metastasis is the critical factor determining tumor-associated mortality in different types of cancer. This is particularly true for uveal melanoma (UM), which almost exclusively metastasizes to the liver. Hepatic stellate cells (HSCs) are the precursors of tumor-associated fibroblasts and support the growth of metastases. However, the underlying mechanisms are widely unknown. Fibroblast growth factor (FGF) signaling is dysregulated in many types of cancer. The aim of this study was to analyze the pro-tumorigenic effects of HSCs on UM cells and the role of FGFs in this crosstalk. Conditioned medium (CM) from activated human HSCs significantly induced proliferation together with enhanced ERK and JNK activation in UM cells. An in silico database analysis revealed that there are almost no mutations of FGF receptors (FGFR) in UM. However, a high FGFR expression was found to be associated with poor survival for UM patients. In vitro, the pro-tumorigenic effects of HSC-CM on UM cells were abrogated by a pharmacological inhibitor (BGJ398) of FGFR1/2/3. The expression analysis revealed that the majority of paracrine FGFs are expressed by HSCs, but not by UM cells, including FGF9. Furthermore, the immunofluorescence analysis indicated HSCs as a cellular source of FGF9 in hepatic metastases of UM patients. Treatment with recombinant FGF9 significantly enhanced the proliferation of UM cells, and this effect was efficiently blocked by the FGFR1/2/3 inhibitor BGJ398. Our study indicates that FGF9 released by HSCs promotes the tumorigenicity of UM cells, and thus suggests FGF9 as a promising therapeutic target in hepatic metastasis.
肝转移是决定不同类型癌症相关肿瘤死亡率的关键因素。这在葡萄膜黑色素瘤 (UM) 中尤其如此,UM 几乎只转移到肝脏。肝星状细胞 (HSCs) 是肿瘤相关成纤维细胞的前体,支持转移瘤的生长。然而,其潜在机制尚不清楚。成纤维细胞生长因子 (FGF) 信号在许多类型的癌症中失调。本研究旨在分析 HSCs 对 UM 细胞的促肿瘤作用以及 FGFs 在这种串扰中的作用。激活的人 HSCs 的条件培养基 (CM) 显著诱导 UM 细胞增殖,并增强 ERK 和 JNK 激活。计算机数据库分析显示,UM 中几乎没有 FGF 受体 (FGFR) 的突变。然而,高 FGFR 表达与 UM 患者的不良预后相关。在体外,HSC-CM 对 UM 细胞的促肿瘤作用被 FGFR1/2/3 的药理学抑制剂 (BGJ398) 阻断。表达分析显示,大多数旁分泌 FGFs 由 HSCs 表达,而不是由 UM 细胞表达,包括 FGF9。此外,免疫荧光分析表明 HSCs 是 UM 患者肝转移中 FGF9 的细胞来源。重组 FGF9 的治疗显著增强了 UM 细胞的增殖,而这种效应被 FGFR1/2/3 抑制剂 BGJ398 有效阻断。我们的研究表明,HSCs 释放的 FGF9 促进了 UM 细胞的致瘤性,因此提示 FGF9 是肝转移治疗的一个有前途的靶点。